secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-167512
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna's miv-cel meets all endpoints in KYSA-8 SPS trial; median T25FW improvement 46% (p=0.0003)
--------------------------------------------------------------------------------

- Single-dose miv-cel achieved statistically significant improvements across all primary and secondary endpoints at Week 16.
- 81% of patients achieved ≥20% improvement in T25FW; 67% of walking-aid users no longer needed assistance.
- All 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.
- Company plans to submit BLA for miv-cel in SPS; data also support potential in myasthenia gravis.
- Natural history study of 153 SPS patients showed minimal improvement with current treatments, underscoring unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526167512/0001193125-26-167512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526167512/kytx-20260421.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-167512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer